Merrimack Pharma (MACK) Tops Q1 EPS by 5c

Merrimack Pharma (NASDAQ: MACK) reported Q1 EPS of ($0.33), $0.05 better than the analyst estimate of ($0.38). Revenue for the quarter came in at $21.3 million versus the consensus estimate of $24.16 million.

For earnings history and earnings-related data on Merrimack Pharma (MACK) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• CAE, Inc. (CAE) Tops Q1 EPS by 2c, Beats on Revenue; Offers FY27 EPS Guidance
• SeaStar Medical (ICU) Misses Q1 EPS by 4c